Kineta, Inc./de: directors' dealings · United States · SEC (Form 4)

About Kineta, Inc./de

Kineta, Inc./DE is a U.S.-listed biotechnology company historically quoted on the NASDAQ market in the United States under ticker KANT. The company’s current corporate form followed a reverse merger with Yumanity Therapeutics that closed in December 2022, after which Yumanity changed its name to Kineta, Inc. In SEC filings, Kineta is described as a clinical-stage biotech headquartered in Mercer Island, Washington, United States.([sec.gov](https://www.sec.gov/Archives/edgar/data/0001445283/000119312522311158/d407996dex991.htm?utm_source=openai)) Kineta’s business was built around next-generation immunotherapies aimed at addressing cancer immune resistance. Its lead program was KVA12123, an anti-VISTA monoclonal antibody designed to target a checkpoint pathway involved in the tumor microenvironment and resistance to immunotherapy. The company also disclosed an anti-CD27 agonist antibody in preclinical development. As a development-stage biotech, Kineta depended on R&D execution, clinical progress, intellectual-property protection, regulatory approvals, and ongoing external financing rather than product sales.([sec.gov](https://www.sec.gov/Archives/edgar/data/1445283/000095017024034676/ka-20231231.htm?utm_source=openai)) From a competitive standpoint, Kineta was a niche, science-driven player in a crowded oncology landscape dominated by larger, better-capitalized pharmaceutical and biotech groups. Its potential differentiation came from its focus on innate immunity and immune-resistance biology, which management highlighted as a path to differentiated immuno-oncology assets. At the same time, Kineta repeatedly disclosed the typical risks of an early-stage public biotech: limited operating history, no commercial revenue, dependence on capital markets, and the need to advance assets through costly clinical milestones.([sec.gov](https://www.sec.gov/Archives/edgar/data/1445283/000095017024034676/ka-20231231.htm?utm_source=openai)) The most important recent development is that TuHURA Biosciences announced and then completed the acquisition of Kineta on June 30, 2025. The transaction included Kineta’s rights to KVA12123, which was renamed TBS-2025. As a result, KANT should be viewed primarily as a legacy public-company story that transitioned into an acquired asset rather than an ongoing standalone listed biotech. For investors, the key takeaway is that Kineta’s value proposition was tied to a single core immuno-oncology platform and ultimately crystallized through M&A rather than independent commercialization.([sec.gov](https://www.sec.gov/Archives/edgar/data/1445283/000095017025091820/kant-20250630.htm?utm_source=openai))